Focused on novel, nanotechnology-based therapeutics
Oliver Fetzer, Ph.D.
President and Chief Executive Officer
David P. DeMagistris, Ph.D.
Senior Vice President, Pharmaceutical Sciences and Manufacturing
Scott Eliasof, Ph.D.
Senior Director, Research
Alexandra Glucksmann, Ph.D.
Senior Vice President, Research and Business Operations
Sandra has been with Cerulean since its founding. Prior to joining Cerulean, she spent 13 years at Millennium Pharmaceuticals which she joined in 1993 as one of its first scientists. At Millennium, she held a series of positions with increasing responsibility, ultimately becoming Vice President of all platform technology groups before moving into a senior role in strategic program management and operations. In this role, she worked closely with the CEO and led company-wide process improvement initiatives and participated in business development and merger and acquisition efforts. During her tenure at Millennium, Sandra was critical in transitioning Millennium from a genomics research-focused organization to a fully integrated pharmaceuticals company with products on the market. Her division played an integral role in the numerous Millennium-large pharmaceutical company collaborations, which generated over $1.8 billion in funding for the company.
Sandra serves on the Board of Directors of Taconic Farms and is the Chair of the Board of Women Entrepreneurs in Science and Technology. She is also a member of Genetics Advisory Council of the Harvard-Partners Center for Personalized Genetic Medicine. Sandra received her B.S. from the University of Wisconsin in Madison, her Ph.D., with honors, from the University of Chicago and completed her post-doctoral training at MIT.
Senior Vice President, Finance and Administration
John Ryan, Ph.D., M.D.
Acting Chief Medical Officer
Jean Silveri, J.D.
Senior Vice President, General Counsel
Senior Director, Pharmaceutical Sciences and Manufacturing
Cissy Young, Ph.D.
Director, Strategy and Business Development